PolTREG S.A. received information on November 21, 2022 that the company’s project entitled “Cell therapy of prediabetes based on artificially multiplied CD4+CD25+CD127- regulatory lymphocytes and antiCD20 antibody” has been qualified for funding from the Medical Research Agency. The total cost of the project is PLN 49.5 million. The grant awarded to the company is PLN 31.7 million, while the project’s implementation period is scheduled for 2022-2028. The condition for the transfer of funds is the signing of a grant agreement. The aim of the project is to conduct Phase II clinical trials.
PolTREG S.A recommended to receive PLN 31.7 million grant from the Medical Research Agency to conduct Phase II clinical trials in cell therapy for prediabetes conditions
See other news
PolTREG appoints Dan Shelly, PhD, MBA as Chief Business Development Officer to help it build partnerships across industry and deliver milestones
Global institutional investors and investment funds hold over 25% of PolTREG’s shares.
Prof. Piotr Trzonkowski co-authors peer-reviewed article showing scientific progress in T-regautoimmune therapy
PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes
The J.P. Morgan Healthcare Conference 2024 is already behind us!
PolTREG at J.P. Morgan Healthcare Conference
PolTREG completes next stage of state-of-the-art manufacturing facility
“The promises of Treg autoimmune therapy – all in one hand” – PolTREG publishes new investor slide deck